Markets

Investment Highlights

Actinogen has recently discovered a completely new way to produce pure Anacardic Acid, currently offered by others for sale at around $1,000.00 per gram!

Anacardic Acid has many varied uses such as in anti-corrosives and new potential growing uses in the nanotechnology area.

The company has lodged provisional patents and/or had significant results for new anti-fungals, antibiotics and bio-degradation of plastic and paper, as well as research in the areas of new organic dyes and extracting metals from ores. 

Equally exciting is that we are also now moving to commercialise a range of biodegradable nappies and other products, containing actinomycetes that should biodegrade much faster than current products. THE GLOBAL MARKET FOR DISPOSABLE NAPPIES ALONE IS ESTIMATED IN EXCESS OF $25 BILLION.  CURRENT DISPOSABLE NAPPIES REPRESENT A LANDFILL AND ENVIRONMENTAL PROBLEM.  They are believed to sometimes take centuries TO BREAK DOWN IN LAND FILL.  Even current biodegradable plastic bags, paper and packaging products without bioactives added, may still take centuries to break down.  We believe this has inhibited the widespread take up of biodegradable products.  With Actinogen eco-friendly actinomycetes included in products in the future this could change very dramatically.

The company has isolated several actinomycetes [streptomycetes] (isolates) that produce bioactive compounds which show significant antibiotic activity against “Superbug” Methicillin Resistance Staphylococcus Aureus (MRSA) also known as Golden Staph and Vancomycin Resistant Enterococci (VRE) bacteria. Subject to further comprehensive testing, the company believes that these bioactive compounds could lead to the development of significant new antibiotics.

The company has lodged samples of the isolates under the Budapest Treaty by lodgement with the National Measurement Institute in Melbourne, Victoria, Australia. The isolates and bioactive compounds are also the subject of a provisional patent application.

The Company intends to seek commercial applications for bioactive compounds produced by soil actinomycetes found in a wide range of environments in Australia. Early focusing on the south west region of Western Australia where the unique soil types have generated a very diverse set of flora and fauna. Many of the soil actinomycetes of this region have not been discovered as yet nor examined in detail.

The Directors include the highly qualified Emeritus Professor Alan Morton, Associate Professor David Keast and Doctor Zhukov (Zeke) Pervan.

The Company has established an arrangement with the PathWest laboratories at the QE II Medical Centre, Sir Charles Gardiner Hospital, Shenton Park, Perth, Western Australia, to utilise laboratories and equipment for carrying out its research into the detection and isolation of the desired actinomycetes and their bioactive compounds.

Investigation of the properties of possible new antibiotics and bioactive compounds for various medical conditions.

The focus on the isolation of actinomycetes in the areas being targeted by the Company includes:

• screening of antimicrobials and antifungals for both human and plant pathogens;
• investigation of pollution control by isolating microorganisms suitable for the disposal and digestion of plastics, oil and toxic chemicals; investigation of the application of microflora to the rehabilitation of salt affected soils; and
• concentration and extraction of various metals in the mining industry.

The company has also identified a series of isolates that are active against clinically important fungal infections and some common agricultural diseases.

The company has identified a series of isolates that are capable of tolerating saline solutions that may have application for the rehabilitation of salt affected soils.